Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Humacyte (Nasdaq: HUMA) announced that founder, President, and CEO Laura Niklason will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 16, 2026, at 11:00am ET. Management will also be available for one-on-one meetings, and a webcast replay will be posted on the company's website. No new clinical, regulatory, or financial details were disclosed; the release only recaps prior milestones such as the December 2024 FDA approval of the ATEV for vascular trauma.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.